- Curia announces a brand refresh, introducing refined corporate messaging and logos for its CDMO services.
- The update includes a new website, enhancing the user experience for contract manufacturing clients.
Curia, a contract research, development, and manufacturing organisation (CDMO), has announced a brand refresh that highlights its capabilities in small molecules, generic active pharmaceutical ingredients (APIs), and biologics. This update, which includes new service logos and a revamped website, aims to strengthen Curia’s messaging and reflect its 30+ years of industry experience.
The brand refresh introduces three distinct commercial service logos, each representing a key service offering within Curia’s portfolio: small molecules, generic APIs, and biologics. The updated website design enhances the user experience for clients seeking CDMO services, including sterile fill-finish and analytical services.
“This refresh reflects our unwavering commitment to being a trusted ally to our customers,” said Philip Macnabb, CEO of Curia. He added that the new brand identity communicates Curia’s expertise and collaborative approach across drug discovery, development, and manufacturing.
Curia, formerly AMRI, has evolved significantly since its founding more than 30 years ago, expanding its focus from small molecules to biologics through acquisitions such as LakePharma and Integrity Bio.
